Sep 23, 2022 04:01 PM
Marksans Pharma announced Q1FY23 Result :
Mark Saldanha, Managing Director of the Company said "We had a strong start to the year, achieving good growth across all our regions. Our existing business, new product approvals, and launches continue to drive the momentum. We have emerged as a prime manufacturer and marketer of private-label store brands of consumer healthcare products in the USA, UK and Australia. This is driven by our commitment to invest in product innovation, newer capacities, and increasing penetration. Looking ahead, we see growing demand in our OTC segment across the regions, and we are well-positioned to take advantage of these opportunities."
|Aug 19, 2022||Dividend||25|
|Sep 15, 2021||Dividend||25|
|Sep 22, 2020||Dividend||10|
Marksans Pharma Limited is a pharmaceutical company and has a market capitalization of Rs. 2,916 crores as of 18th August 2021. The company started on 16th April 1992. The company has reported a total quarterly income of Rs.354.84 crores at the end of June 2021. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 524404 and scrip code MARKSANS. As of 18th August 2021, Marksans Pharma’s shares were trading at Rs. 71.25.
The corporate is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company’s research and development centres are in Verna Goa and Navi Mumbai, respectively. With three manufacturing facilities in India, UK, and therefore the US, Marksans has established an authoritative position in regulated markets in India and abroad. The company currently has approximately 1200 employees globally with more than 500 registered products. It also has 50+ experienced scientists in the R& D facility. The promoter holding stood at 48.25% in June 2021 and has remained constant over the last 15 months. Promoters have zero pledged holdings.
In June 2021, the company reported total revenue of Rs. 354.84 crores as compared to Rs. 336.21 crores during the quarter ended March 2021. It had posted net profit / (loss) of Rs. 62.60 crores for the period ended June 2021 as compared to net profit / (loss) of Rs.79.49 crores for the period ended 31st March 2021. The company’s EPS was at Rs.1.51 for the period ended 30th June '2021, as against Rs.1.93 for the period ended 31st March '2021. On a year-on-year basis, the total income of the company has increased 7.10% from Rs. 331.33 crores to Rs. 354.84 crores with the net profit increasing 26.82% from Rs. 49.36 crores to Rs. 62.60 crores and with EPS increasing 25.83% to Rs. 1.51 as against Rs. 1.2 in June 2020. Over the last 5 years, the company’s market share has increased from 0.49% to 0.54%. Marksans Pharma’s shares closed at Rs. 71.25 (NSE) as of 18th August 2021 and has given a return of 30.38% over the last 12 months.
11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053
Bigshare Services Pvt Ltd
|AGM Date (Month)||:||Sep|
|Face Value Equity Shares||:||1|
|Market Lot Equity Shares||:||1|
|Book Closure Date (Month)||:||Sep|